I

Integer Holdings Corporation

Medical device CDMO for cardiac devices

Regulatory Affairs Specialist 2

Full-TimeUpdated on 10/23/2026
No salary listed
Mid
Bachelor's
Santo Domingo, Dominican Republic
In Person
Biology & BiotechRegulatory & Quality (Life Sciences)

About the job

Requirements
  • At least 1 year of relevant experience is preferred; candidates without the preferred education may be considered with at least 3 years of relevant medical-device or other regulated-industry experience.
  • Demonstrate an understanding of the European Medical Device Regulation, United States Food and Drug Administration regulations, and other applicable regulations identified in the Quality Manual.
  • Demonstrate technical aptitude to contribute to a team or produce technical results individually.
  • Demonstrate written and oral communication competencies.
  • Be highly organized and able to track multiple projects simultaneously.
  • Possess intermediate to advanced skills using Microsoft Office, including PowerPoint, Visio, and Project.
  • Support the Integer Environmental, Health and Safety programs.
Responsibilities
  • Prepare national and international regulatory submissions for Integer-owned devices, support product submissions, and consult multiple sources for submission information.
  • Review Change Requests requiring regulatory review and approval to ensure compliance with national and international government regulations.
  • Prepare and maintain no-file decisions, external regulatory databases such as FDA FURLS, GUDID, and EUDAMED, and product files in accordance with quality-system requirements and department procedures.
  • Coordinate review of and responses to customer requests and queries related to processes and products, and maintain tracking logs.
  • Participate in customer notifications of changes and help maintain the corresponding tracking log.
  • Obtain external regulatory documents, such as CFGs and CFSs, to support customer requests, and facilitate their legalization, authentication, or apostilling as required.
  • Perform and support internal quality-system audits in accordance with Integer quality-system procedures and external requirements in the Integer Quality Manual.
  • Participate as a regulatory team member in regulatory and Notified Body audits, including back-room or front-room activities, and compile, organize, and track responses to findings as needed.
  • Work on projects using Integer’s standard quality-management-system methodologies to investigate process-improvement opportunities.
  • Collaborate with others, exchange information, ask questions, and check for understanding to support development as a regulatory professional.
  • Assure adherence to the Quality Management System, facilitate or contribute to corrective and preventive actions, and contribute to quality KPIs and differentiated-quality goals.
  • Support Integer’s Manufacturing Excellence and Market Focused Innovation strategies.
  • Participate in or lead Site Hoshin Planning, Quality Planning, Validation Master Plans, and related quality-improvement initiatives.
  • Provide data for weekly and monthly QA/RA metrics.
  • Support sustained change by ensuring customer change notifications are initiated and completed as necessary and supporting continuous-improvement activities.
  • Support standardization of workplace organization and visual controls (5S), Manufacturing Standard Work, and training and certification programs where applicable.
  • Promote associate engagement through standardized problem-solving methodologies, behavior-based safety programs, and improvement-idea and suggestion systems.
  • Support systems and process optimization through adoption of built-in-quality principles.
  • Work toward defined goals and objectives, including key projects and expected milestones.
  • Contribute to site quality KPIs and generate continuous-improvement suggestions, supporting their implementation.
Desired Qualifications
  • A bachelor’s degree is preferred.

About the company

I

Integer Holdings Corporation

View

Integer Holdings Corporation is a large medical device contract development and manufacturing organization (CDMO) that supports medical device makers in cardiac rhythm management, neuromodulation, and cardiovascular markets. It provides end-to-end services from design support to manufacturing, delivering components and finished subsystems such as implants, housings, electrodes, and batteries through its Greatbatch Medical, Lake Region Medical, and Electrochem brands. The company differentiates itself by its scale, breadth of capabilities across multiple medical specialties, established brand portfolio, and global manufacturing footprint that enable reliable, integrated supply. Its goal is to improve patients’ lives worldwide by helping customers bring safe and effective medical technologies to market.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Wilmington, Delaware

Founded

1940

Get referred to Integer Holdings Corporation

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue hit $464.1 million, beating estimates despite weak medtech demand.
  • Integer expects demand recovery after New Ross's July 27-August 10, 2026 shutdown.
  • KKR plans new capacity, technology, and employee ownership after closing by year-end 2026.

What critics are saying

  • Integer withdrew 2026 guidance on August 3, 2026, after KKR announced the buyout.
  • Schall, Brown & Schwartz opened an August 23, 2026 fiduciary-duty investigation.
  • Regulatory or stockholder rejection kills the KKR deal and leaves Integer's weak standalone outlook exposed.

What makes Integer Holdings Corporation unique

  • Integer's R&D Velocity integrates design, prototyping, and manufacturing for complex medtech programs.
  • Its 33-facility global network spans electrophysiology, neuromodulation, and structural heart.
  • KKR's August 3, 2026, $5.7 billion bid validates Integer's scale and customer lock-in.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • Adoption Assistance
  • Parental Leave
  • 401(k) Company Match
  • 401(k) Retirement Plan
  • Paid Vacation
  • Paid Holidays

Growth & Insights and Company News

6 month growth

0%

1 year growth

-1%

2 year growth

-1%
Ticker Report
Aug 29th, 2026
Boussard & Gavaudan Gestion Sas Makes New $2.60 Million Investment in Integer Holdings Corporation $ITGR

Boussard & Gavaudan Gestion Sas bought a new position in Integer Holdings Corporation (NYSE:ITGR – Free Report) during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 28,153 shares of the medical equipment provider’s stock, valued at approximately $2,597,000. Other institutional investors and hedge funds also […]

Yahoo Finance
Aug 16th, 2026
Healthcare stocks outpace S&P 500 by 13 percentage points over six months

Healthcare stocks have returned 26.1% over the past six months, outperforming the S&P 500 by 13.1 percentage points. However, investors must remain cautious due to heavy regulation affecting earnings potential. Integer Holdings faces concerns with 6.1% annual revenue growth over two years, lagging healthcare peers. Its modest revenue base of $1.84 billion provides less fixed cost leverage than larger competitors. The company trades at $125.07 per share, or 18.6 times forward price-to-earnings. Evolent Health shows weak platform performance and declining returns on capital. Its high net-debt-to-EBITDA ratio of 7 times could force unfavourable capital raises if market conditions worsen. Shares trade at $4.15, representing 12.4 times forward price-to-earnings. Tenet Healthcare, operating hospitals and surgical centres across nine US states, emerges as the recommended healthcare investment.

Yahoo Finance
Aug 4th, 2026
Integer Holdings acquired by KKR for $5.7B in all-cash deal at $127 per share

Integer Holdings agreed to be acquired by private equity firm KKR in an all-cash deal valued at approximately $5.7 billion. The transaction values the medical technology company at $127 per share. Shares jumped 2.7% in afternoon trading, continuing a rally from the previous session when the stock surged over 20% following the announcement. The acquisition news overshadowed strong second-quarter results, where Integer posted an adjusted profit of $1.60 per share on $464.1 million in revenue, surpassing analyst estimates. Following the buyout announcement, Integer withdrew its previously issued financial guidance and cancelled its upcoming earnings conference call. Shares traded at $124.50, marking a new 52-week high.

BizWire Express
Aug 3rd, 2026
KKR to acquire Integer for $5.7B in all-cash deal at $127 per share

KKR has agreed to acquire Integer Holdings Corporation, a medical device contract development and manufacturing organisation, in an all-cash transaction valued at approximately $5.7 billion. Integer stockholders will receive $127 per share, representing a 51.8% premium to the company's closing share price on 29 April 2026. The acquisition follows a comprehensive strategic review announced by Integer in April 2026. The Integer Board unanimously approved the agreement and recommends stockholder approval. KKR plans to invest in Integer's capacity, technology, innovation, and talent. The firm also intends to establish a broad-based employee ownership programme following the transaction's close, consistent with its approach across portfolio companies. The transaction is expected to close by year-end, subject to stockholder approval and regulatory clearances. Upon completion, Integer will become privately held and delist from the New York Stock Exchange.

Yahoo Finance
Aug 3rd, 2026
Integer Holdings beats Q2 expectations with $464M revenue and $1.60 earnings per share

Integer Holdings Corp. reported second-quarter net income of $23.6 million, or 69 cents per share. Adjusted earnings came to $1.60 per share, exceeding Wall Street expectations of $1.38 per share. The Plano, Texas-based medical device outsource manufacturer posted revenue of $464.1 million for the period, also beating analyst forecasts of $452.5 million. The results surpassed predictions from five analysts surveyed by Zacks Investment Research on both earnings and revenue metrics.